Hemp is one of humanity’s oldest cultivated crops and a cornerstone of sustainable innovation. Traditionally valued for durable fibres, hemp is now gaining renewed attention as a source of non intoxicating cannabinoids such as cannabidiol (CBD). As scientific understanding and public acceptance grow, the industry faces new challenges in scaling from niche applications to global impact. This panel explores hemp’s next development phase, highlighting innovation, regulatory evolution, and collaboration across medicine, wellness, food, and materials sectors.
Tuesday, May 5, 15:00 - 15:45, room Delhi
| Name | Position | Institution |
|---|---|---|
| Dr Julia Hoeng, PhD | VP Innovation & Product Development | Verdeya S.A |
| Name | Position | Institution |
|---|---|---|
| Dr Gavin George, PhD | Cofounder and CEO | Purgene AG |
| Dr Gordon Dawson, PhD | Director, Product Development | Verdeya S.A |
| Prof. Jürg Gertsch | Professor of Biochemistry and Pharmaceutical Biology | University of Bern |
| Dr. Hans Daetwyler, PhD | CEO | Swiss Plant Breeding Center |
| Tonio Schwehr | Applied Economist | EBP Schweiz AG |
Verdeya is pioneering a scientific and responsible, long-term approach to cannabinoids, harnessing nature to address unmet medical and wellbeing needs. With a patient and consumer-first mindset, we develop and commercialize best-in-class medical and non-recreational cannabinoid products. We are doing this by combining scientific strength, world-class technical expertise, and data-driven insights. Verdeya is committed to working with others to create consistent, high standards for cannabinoid quality, safety, and predictability. Verdeya is a wholly owned subsidiary of Aspeya, Inc.
